CDKN2A and esophageal adenocarcinoma: Currently, hgd remains the most reliable predictor of progression to invasive esophageal adenocarcinoma, but potentially promising biomarkers include aneuploidy (dna content greater than 2.7N, or 4N fraction greater than 6%, or both) 95,97, 17p loh and TP53 mutations 96, cyclin D1 protein overexpression 111, and CDKN2A alterations 116,118.